Key result
Drug eluting stents have significantly reduced stent restenosis compared to bare metal stents, while ongoing developments in stent platforms, biodegradable polymers, and bioabsorbable scaffolds aim to address long-term safety concerns like late stent thrombosis.
This review discusses the current status and new developments in drug-eluting stents, focusing on addressing stent thrombosis through advancements in drug and polymer technologies.
Despite the favorable impact of drug eluting stents on stent restenosis, their long-term reliability is considered worrisome by some because of stent thrombosis. Often attributed to adverse reactions to the stent platform, both the drugs and polymer characteristics have been further advanced with current technologies. The present review discussed current drug eluting stents and new developments.
No takes yet. Share an insight, caveat, or question.
Ertaş et al. (2012) conducted a review in Coronary artery disease. Drug eluting stents vs. Bare metal stents and other drug eluting stents was evaluated. Drug eluting stents have significantly reduced stent restenosis compared to bare metal stents, while ongoing developments in stent platforms, biodegradable polymers, and bioabsorbable scaffolds aim to address long-term safety concerns like late stent thrombosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: